Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286 · see citing works

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30251-8 · Cited by 11,907 · see citing works

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897 · see citing works

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Yan, R., Zhang, Y., Li, Y., Xia, L., Guo, Y., & Zhou, Q. (2020) · Science · doi:10.1126/science.abb2762 · Cited by 4,950 · see citing works

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686 · see citing works

Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019

Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., Li, J., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa344 · Cited by 2,607 · see citing works

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Shen, C., Wang, Z., Zhao, F., Yang, Y., Li, J., Yuan, J., Wang, F., Li, D., Yang, M., Xing, L., et al. (2020) · JAMA · doi:10.1001/jama.2020.4783 · Cited by 2,278 · see citing works

RESPIRATORY SYNCYTIAL VIRUS DISEASE IN INFANTS DESPITE PRIOR ADMINISTRATION OF ANTIGENIC INACTIVATED VACCINE12

KIM, H. W., CANCHOLA, J. G., BRANDT, C. D., PYLES, G., CHANOCK, R. M., JENSEN, K., & PARROTT, R. H. (1969) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a120955 · Cited by 1,981 · see citing works

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Duan, K., Liu, B., Li, C., Zhang, H., Yu, T., Qu, J., Zhou, M., Chen, L., Meng, S., Hu, Y., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2004168117 · Cited by 1,962 · see citing works

Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity

Cantuti-Castelvetri, L., Ojha, R., Pedro, L. D., Djannatian, M., Franz, J., Kuivanen, S., van der Meer, F., Kallio, K., Kaya, T., Anastasina, M., et al. (2020) · Science · doi:10.1126/science.abd2985 · Cited by 1,925 · see citing works

Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins

Lam, T. T., Jia, N., Zhang, Y.-W., Shum, M. H.-H., Jiang, J.-F., Zhu, H., Tong, Y., Shi, Y., Ni, X.-B., Liao, Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2169-0 · Cited by 1,877 · see citing works

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

Sekine, T., Perez-Potti, A., Rivera-Ballesteros, O., Strålin, K., Gorin, J.-B., Olsson, A., Llewellyn-Lacey, S., Kamal, H., Bogdanovic, G., Muschiol, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.017 · Cited by 1,788 · see citing works

Viral dynamics in mild and severe cases of COVID-19

Liu, Y., Yan, L.-M., Wan, L., Xiang, T.-X., Le, A., Liu, J.-M., Peiris, M., Poon, L. L. M., & Zhang, W. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30232-2 · Cited by 1,727 · see citing works

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Ju, B., Zhang, Q., Ge, J., Wang, R., Sun, J., Ge, X., Yu, J., Shan, S., Zhou, B., Song, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2380-z · Cited by 1,667 · see citing works

Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2

Zhou, Y., Hou, Y., Shen, J., Huang, Y., Martin, W., & Cheng, F. (2020) · Cell Discovery · doi:10.1038/s41421-020-0153-3 · Cited by 1,588 · see citing works

Developing Covid-19 Vaccines at Pandemic Speed

Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557 · see citing works

Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications

Mathew, D., Giles, J. R., Baxter, A. E., Oldridge, D. A., Greenplate, A. R., Wu, J. E., Alanio, C., Kuri-Cervantes, L., Pampena, M. B., D’Andrea, K., et al. (2020) · Science · doi:10.1126/science.abc8511 · Cited by 1,509 · see citing works

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study

Zheng, S., Fan, J., Yu, F., Feng, B., Lou, B., Zou, Q., Xie, G., Lin, S., Wang, R., Yang, X., et al. (2020) · BMJ · doi:10.1136/bmj.m1443 · Cited by 1,439 · see citing works

Development of an inactivated vaccine candidate for SARS-CoV-2

Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., Yang, M., Li, Y., Zhu, L., Wang, N., Lv, Z., et al. (2020) · Science · doi:10.1126/science.abc1932 · Cited by 1,434 · see citing works

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

Yuan, M., Wu, N. C., Zhu, X., Lee, C.-C. D., So, R. T. Y., Lv, H., Mok, C. K. P., & Wilson, I. A. (2020) · Science · doi:10.1126/science.abb7269 · Cited by 1,405 · see citing works

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Shi, R., Shan, C., Duan, X., Chen, Z., Liu, P., Song, J., Song, T., Bi, X., Han, C., Wu, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2381-y · Cited by 1,286 · see citing works

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Rogers, T. F., Zhao, F., Huang, D., Beutler, N., Burns, A., He, W.-T., Limbo, O., Smith, C., Song, G., Woehl, J., et al. (2020) · Science · doi:10.1126/science.abc7520 · Cited by 1,230 · see citing works

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

Hansen, J., Baum, A., Pascal, K. E., Russo, V., Giordano, S., Wloga, E., Fulton, B. O., Yan, Y., Koon, K., Patel, K., et al. (2020) · Science · doi:10.1126/science.abd0827 · Cited by 1,210 · see citing works

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19

Li, L., Zhang, W. J., Hu, Y., Tong, X., Zheng, S., Yang, J., Kong, Y., Ren, L., Wei, Q., Mei, H., et al. (2020) · JAMA · doi:10.1001/jama.2020.10044 · Cited by 1,207 · see citing works

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells

Cao, Y., Su, B., Guo, X., Sun, W., Deng, Y., Bao, L., Zhu, Q., Zhang, X., Zheng, Y., Geng, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.025 · Cited by 1,188 · see citing works

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Brouwer, P. J. M., Caniels, T. G., van der Straten, K., Snitselaar, J. L., Aldon, Y., Bangaru, S., Torres, J. L., Okba, N. M. A., Claireaux, M., Kerster, G., et al. (2020) · Science · doi:10.1126/science.abc5902 · Cited by 1,140 · see citing works

A human monoclonal antibody blocking SARS-CoV-2 infection

Wang, C., Li, W., Drabek, D., Okba, N. M. A., van Haperen, R., Osterhaus, A. D. M. E., van Kuppeveld, F. J. M., Haagmans, B. L., Grosveld, F. G., & Bosch, B. (2020) · Nature Communications · doi:10.1038/s41467-020-16256-y · Cited by 1,115 · see citing works

Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility

Chan, J., Zhang, A., Yuan, S.-F., Poon, V., Chan, C., Lee, A., Chan, W., Fan, Z., Tsoi, H.-W., Wen, L., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa325 · Cited by 1,034 · see citing works

The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis

Mair-Jenkins, J., Saavedra-Campos, M., Baillie, J. K., Cleary, P. R., Khaw, F.-M., Lim, W. S., Makki, S., Rooney, K., Convalescent Plasma Study Group, Nguyen‐Van‐Tam, J. S., et al. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu396 · Cited by 985 · see citing works

Use of convalescent plasma therapy in SARS patients in Hong Kong

Cheng, Y., Wong, R. S. M., Soo, Y. O. Y., Wong, W. S., Lee, C. K., Ng, M. H. L., Chan, P. K. S., Wong, K. C., Leung, C. B., & Cheng, G. Y.-M. (2004) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1271-9 · Cited by 953 · see citing works

Cross-Reacting Antibodies Enhance Dengue Virus Infection in Humans

Dejnirattisai, W., Jumnainsong, A., Onsirisakul, N., Fitton, P., Vasanawathana, S., Limpitikul, W., Puttikhunt, C., Edwards, C., Duangchinda, T., Supasa, S., et al. (2010) · Science · doi:10.1126/science.1185181 · Cited by 929 · see citing works

The convalescent sera option for containing COVID-19

Casadevall, A., & Pirofski, L. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138003 · Cited by 904 · see citing works

Fc receptor but not complement binding is important in antibody protection against HIV

Hessell, A. J., Hangartner, L., Hunter, M., Havenith, C. E. G., Beurskens, F. J. M., Bakker, J. M., Lanigan, C. M. S., Landucci, G., Forthal, D. N., Parren, P. W. H. I., et al. (2007) · Nature · doi:10.1038/nature06106 · Cited by 899 · see citing works

Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection

Liu, L., Wei, Q., Lin, Q., Fang, J., Wang, H., Kwok, H., Tang, H., Nishiura, K., Peng, J., Tan, Z., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.123158 · Cited by 830 · see citing works

Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody

Halstead, S., & O'Rourke, E. (1977) · The Journal of Experimental Medicine · doi:10.1084/jem.146.1.201 · Cited by 811 · see citing works

Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy

Sridhar, S., Luedtke, A. R., Langevin, E., Zhu, M., Bonaparte, M. I., Machabert, T., Savarino, S. J., Zambrano, B., Moureau, A., Khromava, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800820 · Cited by 792 · see citing works

Neutralization and Antibody-Dependent Enhancement of Dengue Viruses

Halstead, S. B. (2003) · Advances in virus research · doi:10.1016/s0065-3527(03)60011-4 · Cited by 742 · see citing works

A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice

Yang, Z.-Y., Kong, W., Huang, Y., Roberts, A., Murphy, B., Subbarao, K., & Nabel, G. (2004) · Nature · doi:10.1038/nature02463 · Cited by 688 · see citing works

Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry

Wan, Y., Shang, J., Sun, S., Tai, W., Chen, J., Geng, Q., He, L., Chen, Y., Wu, J., Shi, Z., et al. (2019) · Journal of Virology · doi:10.1128/jvi.02015-19 · Cited by 662 · see citing works

Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis

Gralinski, L. E., Sheahan, T. P., Morrison, T. E., Menachery, V. D., Jensen, K., Leist, S. R., Whitmore, A. C., Heise, M. T., & Baric, R. S. (2018) · mBio · doi:10.1128/mbio.01753-18 · Cited by 656 · see citing works

Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus

Tseng, C.-T. K., Sbrana, E., Iwata‐Yoshikawa, N., Newman, P. C., Garron, T. M., Atmar, R. L., Peters, C. J., & Couch, R. B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035421 · Cited by 555 · see citing works

COVID-19: a novel zoonotic disease caused by a coronavirus from China: what we know and what we don’t

Mackenzie, J. S., & Smith, D. W. (2020) · Microbiology Australia · doi:10.1071/ma20013 · Cited by 509 · see citing works

Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures

Hui, K. P. Y., Cheung, M.-C., Perera, R. A. P. M., Ng, K., Bui, C. H. T., Ho, J. C. W., Ng, M. M. T., Kuok, D. I. T., Shih, K. C., Tsao, S., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30193-4 · Cited by 503 · see citing works

A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response upon Challenge

Bolles, M., Deming, D., Long, K., Agnihothram, S., Whitmore, A., Ferris, M., Funkhouser, W., Gralinski, L., Totura, A., Heise, M., et al. (2011) · Journal of Virology · doi:10.1128/jvi.06048-11 · Cited by 477 · see citing works

Early safety indicators of COVID-19 convalescent plasma in 5000 patients

Joyner, M. J., Wright, R. S., Fairweather, D., Senefeld, J. W., Bruno, K. A., Klassen, S. A., Carter, R. E., Klompas, A. M., Wiggins, C. C., Shepherd, J. R. A., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci140200 · Cited by 472 · see citing works

Cytokine Responses in Severe Acute Respiratory Syndrome Coronavirus-Infected Macrophages In Vitro: Possible Relevance to Pathogenesis

Cheung, C. Y., Poon, L. L. M., Ng, I. H. Y., Luk, W., Sia, S. F., Wu, M. H. S., Chan, K., Yuen, K., Gordon, S., Guan, Y., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.12.7819-7826.2005 · Cited by 461 · see citing works

Is COVID-19 receiving ADE from other coronaviruses?

Tetro, J. A. (2020) · Microbes and Infection · doi:10.1016/j.micinf.2020.02.006 · Cited by 437 · see citing works

Highly pathogenic coronavirus N protein aggravates inflammation by MASP-2-mediated lectin complement pathway overactivation

Gao, T., Hu, M., Zhang, X., Li, H., Zhu, L., Liu, H., Dong, Q., Zhang, Z., Wang, Z., Hu, Y., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1101/2020.03.29.20041962 · Cited by 435 · see citing works

Active Replication of Middle East Respiratory Syndrome Coronavirus and Aberrant Induction of Inflammatory Cytokines and Chemokines in Human Macrophages: Implications for Pathogenesis

Zhou, J., Chu, H., Li, C., Wong, B. H., Cheng, Z., Poon, V. K., Sun, T., Lau, C. C.-Y., Wong, K. K. Y., Chan, J. Y. W., et al. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit504 · Cited by 425 · see citing works

Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Zhang, B., Liu, S., Tan, T., Huang, W., Dong, Y., Chen, L., Chen, Q., Zhang, L., Zhong, Q., Zhang, X., et al. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.03.039 · Cited by 421 · see citing works

Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice

Bisht, H., Roberts, A., Vogel, L., Bukreyev, A. A., Collins, P. L., Murphy, B. R., Subbarao, K., & Moss, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401939101 · Cited by 415 · see citing works

OBSTETRIC DELIVERY TODAY

Dunn, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91624-x · Cited by 415 · see citing works

Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection

DiLillo, D. J., Palese, P., Wilson, P. C., & Ravetch, J. V. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84428 · Cited by 409 · see citing works

Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity

Larsen, M. D., de Graaf, E. L., Sonneveld, M. E., Plomp, H. R., Nouta, J., Hoepel, W., Chen, H.-J., Linty, F., Visser, R., Brinkhaus, M., et al. (2021) · Science · doi:10.1126/science.abc8378 · Cited by 408 · see citing works

A Role for Immune Complexes in Enhanced Respiratory Syncytial Virus Disease

Polack, F. P., Teng, M. N., Collins, P. L., Prince, G. A., Exner, M., Regele, H. M., Lirman, D. D., Rabold, R., Hoffman, S. J., Karp, C. L., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020781 · Cited by 398 · see citing works

Against pandemic research exceptionalism

London, A. J., & Kimmelman, J. (2020) · Science · doi:10.1126/science.abc1731 · Cited by 375 · see citing works

IgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity

Wang, T. T., Sewatanon, J., Memoli, M. J., Wrammert, J., Bournazos, S., Bhaumik, S. K., Pinsky, B. A., Chokephaibulkit, K., Onlamoon, N., Pattanapanyasat, K., et al. (2017) · Science · doi:10.1126/science.aai8128 · Cited by 371 · see citing works

ANTIBODY-DEPENDENT ENHANCEMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTION

Robinson, W. E., Montefiori, D. C., & Mitchell, W. M. (1988) · The Lancet · doi:10.1016/s0140-6736(88)91657-1 · Cited by 358 · see citing works

Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea

Ahn, J. Y., Sohn, Y., Lee, S. H., Cho, Y., Hyun, J. H., Baek, Y. J., Jeong, S. J., Kim, J. H., Ku, N. S., Yeom, J., et al. (2020) · Journal of Korean Medical Science · doi:10.3346/jkms.2020.35.e149 · Cited by 352 · see citing works

Adverse effects of plasma transfusion

Pandey, S., & Vyas, G. N. (2012) · Transfusion · doi:10.1111/j.1537-2995.2012.03663.x · Cited by 351 · see citing works

Immunization with Modified Vaccinia Virus Ankara-Based Recombinant Vaccine against Severe Acute Respiratory Syndrome Is Associated with Enhanced Hepatitis in Ferrets

Weingartl, H. M., Czub, M., Czub, S., Neufeld, J., Marszal, P., Gren, J., Smith, G. A., Jones, S. E., Proulx, R., Deschambault, Y., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.22.12672-12676.2004 · Cited by 344 · see citing works

Challenges of Convalescent Plasma Infusion Therapy in Middle East Respiratory Coronavirus Infection: A Single Centre Experience

Ko, J. H., Seok, H., Cho, S. Y., Ha, Y. E., Baek, J. Y., Ys, K., Kim, Y., Park, J. K., Chung, C. R., Kang, E., et al. (2017) · Antiviral Therapy · doi:10.3851/imp3243 · Cited by 323 · see citing works

Anti-Severe Acute Respiratory Syndrome Coronavirus Spike Antibodies Trigger Infection of Human Immune Cells via a pH- and Cysteine Protease-Independent FcγR Pathway

Jaume, M., Yip, M., Cheung, C. Y., Leung, N., Li, P. H., Kien, F., Dutry, I., Callendret, B., Escriou, N., Altmeyer, R. M., et al. (2011) · Journal of Virology · doi:10.1128/jvi.00671-11 · Cited by 312 · see citing works

Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates

Wang, Q., Zhang, L., Kuwahara, K., Li, L., Liu, Z., Li, T., Zhu, H., Liu, J., Xu, Y., Xie, J., et al. (2016) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.6b00006 · Cited by 297 · see citing works

Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization

Vennema, H., de Groot, R. J., Harbour, D. A., Dalderup, M. J. M., Gruffydd-Jones, T., Horzinek, M. C., & Spaan, W. J. M. (1990) · Journal of Virology · doi:10.1128/jvi.64.3.1407-1409.1990 · Cited by 276 · see citing works

Vaccine Efficacy in Senescent Mice Challenged with Recombinant SARS-CoV Bearing Epidemic and Zoonotic Spike Variants

Deming, D., Sheahan, T. P., Heise, M. T., Yount, B. L., Davis, N., Sims, A. M., Suthar, M. S., Harkema, J. R., Whitmore, A. C., Pickles, R. J., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030525 · Cited by 273 · see citing works

Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus

Agrawal, A. S., Tao, X., Algaissi, A. A., Garron, T. M., Narayanan, K., Peng, B., Couch, R. B., & Tseng, C.-T. K. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1177688 · Cited by 267 · see citing works

Mucosal immunisation of African green monkeys ( Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS

Bukreyev, A. A., Lamirande, E. W., Buchholz, U. J., Vogel, L., Elkins, W. R., Claire, M. S., Murphy, B. R., Subbarao, K., & Collins, P. L. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16501-x · Cited by 256 · see citing works

Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus

Yip, M., Leung, N., Cheung, C. Y., Li, P. H., Lee, H. H. Y., Daëron, M., Peiris, M. J. S., Bruzzone, R., & Jaume, M. (2014) · Virology Journal · doi:10.1186/1743-422x-11-82 · Cited by 249 · see citing works

Prior Immunization with Severe Acute Respiratory Syndrome (SARS)-Associated Coronavirus (SARS-CoV) Nucleocapsid Protein Causes Severe Pneumonia in Mice Infected with SARS-CoV

Yasui, F., Kai, C., Kitabatake, M., Inoue, S., Yoneda, M., Yokochi, S., Kase, R., Sekiguchi, S., Morita, K., Hishima, T., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.9.6337 · Cited by 248 · see citing works

Antibody-mediated enhancement of disease in feline infectious peritonitis: Comparisons with dengue hemorrhagic fever

Weiss, R. C., & Scott, F. W. (1981) · Comparative Immunology Microbiology and Infectious Diseases · doi:10.1016/0147-9571(81)90003-5 · Cited by 242 · see citing works

Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant

Zeitlin, L., Pettitt, J., Scully, C., Bohorova, N., Kim, D., Pauly, M. H., Hiatt, A., Ngo, L. H., Steinkellner, H., Whaley, K. J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108360108 · Cited by 229 · see citing works

Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcγRII-dependent entry into B cells in vitro

Kam, Y., Kien, F., Roberts, A., Cheung, Y. C., Lamirande, E. W., Vogel, L., Chu, S. L., Tse, J., Guarner, J., Zaki, S. R., et al. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.08.011 · Cited by 209 · see citing works

Antibody-Dependent Enhancement of Ebola Virus Infection

Takada, A., Feldmann, H., Ksiazek, T. G., et al. (2003) · Journal of Virology · doi:10.1128/jvi.77.13.7539-7544.2003 · Cited by 206 · see citing works

Severe Acute Respiratory Syndrome-Associated Coronavirus Vaccines Formulated with Delta Inulin Adjuvants Provide Enhanced Protection while Ameliorating Lung Eosinophilic Immunopathology

Honda‐Okubo, Y., Barnard, D. L., Ong, C. H., Peng, B., Tseng, C.-T. K., & Petrovsky, N. (2014) · Journal of Virology · doi:10.1128/jvi.02980-14 · Cited by 204 · see citing works

Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets

CZUB, M., WEINGARTL, H., CZUB, S., HE, R., & CAO, J. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.01.033 · Cited by 180 · see citing works

A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles

Polack, F. P., Hoffman, S. J., Crujeiras, G., et al. (2003) · Nature Medicine · doi:10.1038/nm918 · Cited by 163 · see citing works

Neutralizing Antibody Response and SARS Severity

Ho, M., Chen, W., Chen, H., Lin, S.-F., Wang, M.-C., Di, J., Lu, Y., Liu, C., Chang, S., Chao, C.-L., et al. (2005) · Emerging infectious diseases · doi:10.3201/eid1111.040659 · Cited by 138 · see citing works

Antibody-dependent enhancement of SARS coronavirus infection and its role in the pathogenesis of SARS.

Yip, M., Leung, N., Li, P. H., Cheung, C. Y., Dutry, I., Li, D., Daëron, M., Bruzzone, R., Peiris, M. J. S., & Jaume, M. (2016) · PubMed · Cited by 123 · see citing works

Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy

Hiatt, A., Bohorova, N., Bohorov, O., Goodman, C. A., Kim, D., Pauly, M. H., Velasco, J., Whaley, K. J., Piedra, P. A., Gilbert, B. E., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402458111 · Cited by 119 · see citing works

Analysis of Serologic Cross-Reactivity Between Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen MicroarrayPreprint

Khan, S., Nakajima, R., Jain, A., de Assis, R. R., Jasinskas, A., Obiero, J. M., Adenaiye, O., Tai, S., Hong, F. H., Milton, D. K., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.24.006544 · Cited by 118 · see citing works

Infectivity-Enhancing Antibodies to Ebola Virus Glycoprotein

Takada, A., Watanabe, S., Okazaki, K., et al. (2001) · Journal of Virology · doi:10.1128/jvi.75.5.2324-2330.2001 · Cited by 113 · see citing works

Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1-infected and passively immunized chimpanzees.

Robinson, W. E., Montefiori, D. C., Mitchell, W. M., Prince, A. M., Alter, H. J., Dreesman, G. R., & Eichberg, J. W. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.12.4710 · Cited by 108 · see citing works

Atypical Measles and Enhanced Respiratory Syncytial Virus Disease (ERD) Made Simple

Polack, F. P. (2007) · Pediatric Research · doi:10.1203/pdr.0b013e3180686ce0 · Cited by 105 · see citing works

Atypical exanthem following exposure to natural measles: Eleven cases in children previously inoculated with killed vaccine

Nader, P. R., Horwitz, M. S., & Rousseau, J. (1968) · The Journal of Pediatrics · doi:10.1016/s0022-3476(68)80396-8 · Cited by 102 · see citing works

Antibody-Dependent Enhancement of Feline Infectious Peritonitis Virus Infection in Feline Alveolar Macrophages and Human Monocyte Cell Line U937 by Serum of Cats Experimentally or Naturally Infected with Feline Coronavirus.

Hohdatsu, T., Yamada, M., TOMINAGA, R., MAKINO, K., Kida, K., & Koyama, H. (1998) · Journal of Veterinary Medical Science · doi:10.1292/jvms.60.49 · Cited by 97 · see citing works

Antibody-Dependent Enhancement Occurs Upon Re-Infection with the Identical Serotype Virus in Feline Infectious Peritonitis Virus Infection

Takano, T., KAWAKAMI, C., Yamada, S., et al. (2008) · Journal of Veterinary Medical Science · doi:10.1292/jvms.70.1315 · Cited by 94 · see citing works

Vaccines against respiratory syncytial virus: The time has finally come

Graham, B. S. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.04.083 · Cited by 92 · see citing works

Cross-lineage protection by human antibodies binding the influenza B hemagglutinin

Liu, Y., Tan, H., Koutsakos, M., Jegaskanda, S., Esterbauer, R., Tilmanis, D., Aban, M., Kedzierska, K., Hurt, A. C., Kent, S. J., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08165-y · Cited by 88 · see citing works

A study on the mechanism of antibody-dependent enhancement of feline infectious peritonitis virus infection in feline macrophages by monoclonal antibodies

Hohdatsu, T., Nakamura, M., Ishizuka, Y., et al. (1991) · Archives of Virology · doi:10.1007/bf01310476 · Cited by 86 · see citing works

Antibody-dependent enhancement of influenza disease promoted by increase in hemagglutinin stem flexibility and virus fusion kinetics

Winarski, K. L., Tang, J., Klenow, L., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821317116 · Cited by 85 · see citing works

Fc-dependent functions are redundant to efficacy of anti-HIV antibody PGT121 in macaques

Parsons, M. S., Lee, W. S., Kristensen, A. B., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci122466 · Cited by 84 · see citing works

Phagocytic cells contribute to the antibody-mediated elimination of pulmonary-infected SARS coronavirus

Yasui, F., Kohara, M., Kitabatake, M., Nishiwaki, T., Fujii, H., Tateno, C., Yoneda, M., Morita, K., Matsushima, K., Koyasu, S., et al. (2014) · Virology · doi:10.1016/j.virol.2014.02.005 · Cited by 83 · see citing works

Evaluation of Antibody-Dependent Enhancement of SARS-CoV Infection in Rhesus Macaques Immunized with an Inactivated SARS-CoV Vaccine

Luo, F., Liao, F., Wang, H., Tang, H.-B., Yang, Z.-Q., & Hou, W. (2018) · Virologica Sinica · doi:10.1007/s12250-018-0009-2 · Cited by 82 · see citing works

Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine

Qin, E.-D., Shi, H., Tang, L., Wang, C., Chang, G., Ding, Z., Zhao, K., Wang, J., Chen, Z., Yu, M., et al. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.06.038 · Cited by 75 · see citing works

Characterization of rat cecum cellulolytic bacteria

Montgomery, L., & Macy, J. M. (1982) · Applied and Environmental Microbiology · doi:10.1128/aem.44.6.1435-1443.1982 · Cited by 73 · see citing works

A Highly Immunogenic, Protective, and Safe Adenovirus-Based Vaccine Expressing Middle East Respiratory Syndrome Coronavirus S1-CD40L Fusion Protein in a Transgenic Human Dipeptidyl Peptidase 4 Mouse Model

Hashem, A. M., Algaissi, A. A., Agrawal, A. S., Alamri, S. S., Alhabbab, R. Y., Sohrab, S. S., Almasoud, A. S., Alharbi, N. K., Peng, B., Russell, M. S., et al. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz137 · Cited by 72 · see citing works

Mind the Gap: How Interspecies Variability in IgG and Its Receptors May Complicate Comparisons of Human and Non-human Primate Effector Function

Crowley, A. R., & Ackerman, M. E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00697 · Cited by 68 · see citing works

Influenza-Specific Antibody-Dependent Phagocytosis

Ana‐Sosa‐Batiz, F., Vanderven, H. A., Jegaskanda, S., Johnston, A. P. R., Rockman, S. P., Laurie, K., Barr, I., Reading, P. C., Lichtfuss, M., & Kent, S. J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154461 · Cited by 64 · see citing works

Pathogenesis of oral type I feline infectious peritonitis virus (FIPV) infection: Antibody-dependent enhancement infection of cats with type I FIPV via the oral route

Takano, T., Yamada, S., Doki, T., & Hohdatsu, T. (2019) · Journal of Veterinary Medical Science · doi:10.1292/jvms.18-0702 · Cited by 63 · see citing works

Infection enhancement of influenza A NWS virus in primary murine macrophages by anti‐hemagglutinin monoclonal antibody

Ochiai, H., Kurokawa, M., Matsui, S., et al. (1992) · Journal of Medical Virology · doi:10.1002/jmv.1890360312 · Cited by 62 · see citing works

Compartmentalization of Immune Response and Microbial Translocation in Decompensated Cirrhosis

Silva, M. C. A., Schierwagen, R., Pohlmann, A., Magdaleno, F., Uschner, F. E., Ryan, P. B., Vehreschild, M. J. G. T., Clària, J., Latz, E., Lelouvier, B., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00069 · Cited by 52 · see citing works

Antibody-Dependent Cell-Mediated Cytotoxicity Epitopes on the Hemagglutinin Head Region of Pandemic H1N1 Influenza Virus Play Detrimental Roles in H1N1-Infected Mice

Ye, Z., Yuan, S., Poon, V. K., Wen, L., Yang, D., Sun, Z., Li, C., Meng, H., Shuai, H., Zhou, J., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00317 · Cited by 37 · see citing works

A Tale of Two Viruses: Does Heterologous Flavivirus Immunity Enhance Zika Disease?

Sariol, C. A., Nogueira, M. L., & Vasilakis, N. (2017) · Trends in Microbiology · doi:10.1016/j.tim.2017.10.004 · Cited by 35 · see citing works

Neutralizing monoclonal antibodies for treatment of COVID-19

Taylor, P. C., Adams, A. C., Hufford, M. M., de la Torre, I., Winthrop, K., & Gottlieb, R. L. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00542-x · Cited by 732 · see citing works

The dawn of mRNA vaccines: the COVID-19 case

Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.03.043 · Cited by 504 · see citing works

Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection

Winkler, E. S., Gilchuk, P., Yu, J., Bailey, A. L., Chen, R. E., Chong, Z., Zost, S. J., Jang, H., Huang, Y., Allen, J. D., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.026 · Cited by 366 · see citing works

COVID-19 vaccines: The status and perspectives in delivery points of view

Chung, J. Y., Thone, M. N., & Kwon, Y. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.011 · Cited by 375 · see citing works

mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents

Rauch, S., Roth, N., Schwendt, K., Fotin-Mleczek, M., Mueller, S. O., & Petsch, B. (2021) · npj Vaccines · doi:10.1038/s41541-021-00311-w · Cited by 165 · see citing works

Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice

Spencer, A. J., McKay, P. F., Belij-Rammerstorfer, S., Ulaszewska, M., Bissett, C. D., Hu, K., Samnuan, K., Blakney, A. K., Wright, D., Sharpe, H. R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23173-1 · Cited by 125 · see citing works

Development of mRNA Vaccines: Scientific and Regulatory Issues

Knezevic, I., Liu, M. A., Peden, K., Zhou, T., & Kang, H.-N. (2021) · Vaccines · doi:10.3390/vaccines9020081 · Cited by 114 · see citing works

Tackling COVID-19 with neutralizing monoclonal antibodies

Corti, D., Purcell, L. A., Snell, G., & Veesler, D. (2021) · Cell · doi:10.1016/j.cell.2021.07.027 · Cited by 78 · see citing works

Acute mesenteric ischemia in patients with COVID-19: review of the literature

Chen, C., Li, Y.-W., Shi, P.-F., & Qian, S.-X. (2022) · Journal of the National Medical Association · doi:10.1016/j.jnma.2021.12.003 · Cited by 14 · see citing works

Cellular and Molecular Basis of Antibody-Dependent Enhancement in Human Dengue Pathogenesis

Jin, X. (2008) · Future Virology · doi:10.2217/17460794.3.4.343 · Cited by 5 · see citing works

Deeper understanding about the genetic structure of dengue virus using SVM

Choi, S., Choi, H., & Yoon, T. (2016) · MATEC Web of Conferences · doi:10.1051/matecconf/20166901008

Dengue virus: molecular basis of cell entry and pathogenesis, 25–27 June 2003, Vienna, Austria

Halstead, S. B., Heinz, F. X., Barrett, A. D. T., & Roehrig, J. T. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.03.069 · Cited by 80 · see citing works

Development of a Novel Assay to Assess the Avidity of Dengue Virus-Specific Antibodies Elicited in Response to a Tetravalent Dengue Vaccine

Tsuji, I., Dominguez, D., Egan, M. A., & Dean, H. J. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab064 · Cited by 17 · see citing works

Lipidated Dengue-2 Envelope Protein Domain III Independently Stimulates Long-Lasting Neutralizing Antibodies and Reduces the Risk of Antibody-Dependent Enhancement

Chiang, C.-Y., Pan, C.-H., Hsieh, C.-H., et al. (2013) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0002432 · Cited by 36 · see citing works